NCT05590728View on ClinicalTrials.gov

Safety of Intravenous Apramycin in Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 16, 2023

Primary Completion Date

October 22, 2023

Study Completion Date

October 22, 2023

Conditions
Bacterial Infection
Interventions
DRUG

Apramycin (EBL-1003)

A mono-substituted 2-deoxystreptamine comprising a unique bicyclic octadiose moiety. It is a crystalline free base of the amoniglycoside apramycin.

Trial Locations (1)

37920

Alliance for Multispecialty Research, LLC - Knoxville, Knoxville

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH